Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P04155

UPID:
TFF1_HUMAN

ALTERNATIVE NAMES:
Breast cancer estrogen-inducible protein; PNR-2; Polypeptide P1.A; Protein pS2

ALTERNATIVE UPACC:
P04155

BACKGROUND:
The protein Trefoil factor 1, with its alternative identities such as Breast cancer estrogen-inducible protein and Protein pS2, is pivotal in safeguarding the gastrointestinal mucosa. It ensures the stability of the mucous gel barrier, protecting against harmful agents. This protein's role extends to possibly preventing the formation of calcium oxalate crystals in the urinary tract, indicating its broad biological impact.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Trefoil factor 1 opens up avenues for innovative therapeutic approaches. Its critical function in protecting the gastrointestinal mucosa and potential in urinary health underscores its importance in developing treatments for related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.